Macular Degeneration Treatments

Macular Degeneration Treatments in Medford

According to EYEWiki:

Drug Treatments

The proliferation of abnormal blood vessels in the retina is stimulated by vascular endothelial growth factor (VEGF). Antiangiogenics or anti-VEGF agents can cause regression of the abnormal blood vessels and improve vision when injected directly into the vitreous humor of the eye. The injections must be repeated monthly or bimonthly. Several antiangiogenic drugs have been approved for use in the eye by the U.S. Food and Drug Administration and regulatory agencies in other countries.

Optical coherence tomography and anti-vascular endothelial growth factor (VEGF) therapy together have revolutionized the treatment of exudative ARMD. Ranabizumab (Lucentis, Genentech, San Francisco, CA), Bevacizumab (Avastin, Genentech, San Francisco, CA), and more recently, Aflibercept (Eylea, Regeneron Pharmaceuticals Inc., Tarrytown, NY), are frequently used in the treatment of exudative ARMD. Pegaptanib (Macugen, Pfizer) was the first anti-VEGF therapy to recieive FDA approval for the treatment of ARMD in 2004.  It is biochemically distinct from subsequent anti-VEGF agents, in that it represents an aptamer as opposed to a monoclonal antibody (Bevacizumab), monoclonal antibody fragment (Ranabizumab), or a receptor-antibody fusion protein. Pegaptanib is a small oligonucleic acid molecule that binds specifically to the VEGF-165 isoform. 

Photodynamic therapy (PDT) has also been used to treat wet AMD. The drug verteporfin is administered intravenously; light of the correct wavelength is then applied to the abnormal blood vessels. This activates the verteporfin and obliterates the vessels.

Nondrug interventions

Some evidence supports a reduction in the risk of AMD with increasing intake of two carotenoids, lutein and zeaxanthin.

Consuming omega-3 fatty acids (docosahexaenoic acid and eicosapentaenoic acid) has been correlated with a reduced progression of early AMD, and in conjunction with low glycemic index foods, with reduced progression of advanced AMD.

A Cochrane Database Review of publications to 2012 found the use of vitamin and mineral supplements, alone or in combination, by the general population had no effect on AMD, a finding echoed by another review. A 2006 Cochrane Review of the effects of vitamins and minerals on the slowing of AMD found the positive results mainly came from a single large trial in the United States (the Age-Related Eye Disease Study), with funding from the eye care product company Bausch & Lomb, which also manufactured the supplements used in the study, and questioned the generalization of the data to any other populations with different nutritional status. The review also questioned the possible harm of such supplements, given the increased risk of lung cancer in smokers with high intakes of beta-carotene, and the increased risk of heart failure in at-risk populations who consume high levels of vitamin E supplements. A Cochrane database review published in March 2012 did not find sufficient evidence to determine the effectiveness and safety of statins for the prevention or delaying the progression of AMD.

More information located at the link below:

Age Related Macular Degeneration Treatments

For more information on macular degeneration or to make an appointment with Oregon Retina Center for macular degeneration treatment call our Medford Office at (541) 770-2020 today.